Press releases
You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.
Filter by
-
GSK starts phase III study with mepolizumab in patients with nasal polyps
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizum...
Read more -
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
Read more -
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
Read more -
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
GSK today announced results from a 10-year continuation study, which showed that Benlysta (belimu...
Read more -
GSK and MMV announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced positive results from two phase III s...
Read more -
Four innovations to tackle under-five deaths win US$1 million Healthcare Innovation Award from GSK and Save the Children
Organisations in Pakistan, Colombia, India and Nigeria recognised for innovations helping the har...
Read more -
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising ...
Read more -
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level
GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase III...
Read more -
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients ...
Read more -
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced preliminary results of two pivotal phase III s...
Read more -
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an...
Read more -
GSK delivers another quarter of continued progress
GSK delivers another quarter of continued progress Q1 sales of £7.4 billion, +19% AER, + 5% CER ...
Read more -
GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Follows regulatory submissions in US, EU and Canada
Read more -
Togo becomes first country in Africa to validate the elimination of lymphatic filariasis as a public health problem
LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted t...
Read more -
GSK makes change to financial reporting framework
GSK keeps its financial reporting framework under regular review to ensure that it remains curren...
Read more -
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
Read more -
GSK announces new scholarships to recognise retiring CEO Sir Andrew Witty’s contribution to global health
GSK today announced a new partnership with the London School of Hygiene & Tropical Medicine to es...
Read more -
UK Biobank, GSK and Regeneron announce largest gene sequencing initiative on world’s most detailed health database to improve drug discovery and disease diagnosis
Groundbreaking UK/US initiative will deliver first data within a year
Read more -
GSK’s MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
MUSCA study shows asthma patients achieved improvements in their health-related quality of life a...
Read more -
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
GSK today announced the closure of an agreement with Aspen aligned with GSK’s strategy of simplif...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company on a mission: we want to help people do more, feel better, live longer
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
